Marco V Perez1, Aleksandra Pavlovic1, Ching Shang1, Matthew T Wheeler1, Clint L Miller1, Jing Liu1, Frederick E Dewey1, Stephen Pan1, Porama K Thanaporn1, Devin Absher2, Jeffrey Brandimarto3, Heidi Salisbury1, Khin Chan1, Rupak Mukherjee4, Roda P Konadhode5, Richard M Myers2, Daniel Sedehi6, Thomas E Scammell7, Thomas Quertermous1, Thomas Cappola3, Euan A Ashley8. 1. Center for Inherited Cardiovascular Disease, Division of Cardiovascular Medicine, Stanford University, Stanford, California. 2. Hudson Alpha Institute for Biotechnology, Huntsville, Alabama. 3. Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 4. Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, South Carolina. 5. Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina. 6. Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio. 7. Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. 8. Center for Inherited Cardiovascular Disease, Division of Cardiovascular Medicine, Stanford University, Stanford, California. Electronic address: euan@stanford.edu.
Abstract
BACKGROUND: The genetic determinants of heart failure (HF) and response to medical therapy remain unknown. We hypothesized that identifying genetic variants of HF that associate with response to medical therapy would elucidate the genetic basis of cardiac function. OBJECTIVES: This study sought to identify genetic variations associated with response to HF therapy. METHODS: This study compared extremes of response to medical therapy in 866 HF patients using a genome-wide approach that informed the systems-based design of a customized single nucleotide variant array. The effect of genotype on gene expression was measured using allele-specific luciferase reporter assays. Candidate gene transcription-deficient mice underwent echocardiography and treadmill exercise. The ability of the target gene agonist to rescue mice from chemically-induced HF was assessed with echocardiography. RESULTS: Of 866 HF patients, 136 had an ejection fraction improvement of 20% attributed to resynchronization (n = 83), revascularization (n = 7), tachycardia resolution (n = 2), alcohol cessation (n = 1), or medications (n = 43). Those with the minor allele for rs7767652, upstream of hypocretin (orexin) receptor-2 (HCRTR2), were less likely to have improved left ventricular function (odds ratio: 0.40 per minor allele; p = 3.29 × 10(-5)). In a replication cohort of 798 patients, those with a minor allele for rs7767652 had a lower prevalence of ejection fraction >35% (odds ratio: 0.769 per minor allele; p = 0.021). In an HF model, HCRTR2-deficient mice exhibited poorer cardiac function, worse treadmill exercise capacity, and greater myocardial scarring. Orexin, an HCRTR2 agonist, rescued function in this HF mouse model. CONCLUSIONS: A systems approach identified a novel genetic contribution to human HF and a promising therapeutic agent efficacious in an HF model.
BACKGROUND: The genetic determinants of heart failure (HF) and response to medical therapy remain unknown. We hypothesized that identifying genetic variants of HF that associate with response to medical therapy would elucidate the genetic basis of cardiac function. OBJECTIVES: This study sought to identify genetic variations associated with response to HF therapy. METHODS: This study compared extremes of response to medical therapy in 866 HF patients using a genome-wide approach that informed the systems-based design of a customized single nucleotide variant array. The effect of genotype on gene expression was measured using allele-specific luciferase reporter assays. Candidate gene transcription-deficient mice underwent echocardiography and treadmill exercise. The ability of the target gene agonist to rescue mice from chemically-induced HF was assessed with echocardiography. RESULTS: Of 866 HF patients, 136 had an ejection fraction improvement of 20% attributed to resynchronization (n = 83), revascularization (n = 7), tachycardia resolution (n = 2), alcohol cessation (n = 1), or medications (n = 43). Those with the minor allele for rs7767652, upstream of hypocretin (orexin) receptor-2 (HCRTR2), were less likely to have improved left ventricular function (odds ratio: 0.40 per minor allele; p = 3.29 × 10(-5)). In a replication cohort of 798 patients, those with a minor allele for rs7767652 had a lower prevalence of ejection fraction >35% (odds ratio: 0.769 per minor allele; p = 0.021). In an HF model, HCRTR2-deficient mice exhibited poorer cardiac function, worse treadmill exercise capacity, and greater myocardial scarring. Orexin, an HCRTR2 agonist, rescued function in this HF mouse model. CONCLUSIONS: A systems approach identified a novel genetic contribution to human HF and a promising therapeutic agent efficacious in an HF model.
Authors: Douglas S Lee; Michael J Pencina; Emelia J Benjamin; Thomas J Wang; Daniel Levy; Christopher J O'Donnell; Byung-Ho Nam; Martin G Larson; Ralph B D'Agostino; Ramachandran S Vasan Journal: N Engl J Med Date: 2006-07-13 Impact factor: 91.245
Authors: M López; R Señarís; R Gallego; T García-Caballero; F Lago; L Seoane; F Casanueva; C Diéguez Journal: Endocrinology Date: 1999-12 Impact factor: 4.736
Authors: Paul A Heidenreich; Justin G Trogdon; Olga A Khavjou; Javed Butler; Kathleen Dracup; Michael D Ezekowitz; Eric Andrew Finkelstein; Yuling Hong; S Claiborne Johnston; Amit Khera; Donald M Lloyd-Jones; Sue A Nelson; Graham Nichol; Diane Orenstein; Peter W F Wilson; Y Joseph Woo Journal: Circulation Date: 2011-01-24 Impact factor: 29.690
Authors: Marlene A Wilson; Israel Liberzon; Merry L Lindsey; Yana Lokshina; Victoria B Risbrough; Renu Sah; Susan K Wood; John B Williamson; Francis G Spinale Journal: Stress Date: 2019-06-04 Impact factor: 3.493